NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 27, 2018

Primary Completion Date

May 16, 2019

Study Completion Date

July 15, 2019

Conditions

Common WartWarts HandWartsPapillomavirus InfectionsDNA Virus InfectionsSkin Diseases, ViralSkin Diseases, InfectiousSkin DiseasesVirus DiseasesTumor Virus InfectionsVerruca VulgarisVerruca

Interventions

COMBINATION_PRODUCT

VP-102 Cantharidin topical film forming solution

VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.

COMBINATION_PRODUCT

VP-102 Cantharidin, topical film forming solution

VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.

Trial Locations (5)

27612

Cohort 1-Wake Research Associates, Raleigh

32256

Cohort 2: Solutions Through Advanced Research, Jacksonville

46168

Cohort 2: The Indiana Clinical Trials Center, Plainfield

48346

Cohort 2: Clarkston Skin Research, Clarkston

72212

Cohort 2: Applied Research Center of Arkansas, Little Rock